(Q38531008)

3 September 2017

1 reference

title

Central Reading of Endoscopy Endpoints in Inflammatory Bowel Disease Trials (English)

1 reference

inflammatory bowel diseases

3 September 2017

1 reference

1 reference

based on heuristic

inferred from title

author

William Jeffery Sandborn

series ordinal

5

object named as

William J Sandborn

1 reference

3 September 2017

3

Brian Feagan

1 reference

3 September 2017

6

Paul Rutgeerts

1 reference

3 September 2017

Klaus Gottlieb

1

1 reference

3 September 2017

Simon Travis

series ordinal

2

1 reference

3 September 2017

Fez Hussain

series ordinal

4

1 reference

3 September 2017

publication date

18 June 2015

1 reference

Inflammatory Bowel Diseases

3 September 2017

number of pages

8

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

3 September 2017

volume

21

1 reference

3 September 2017

issue

10

1 reference

3 September 2017

page(s)

2475-2482

1 reference

Biomarkers and surrogate endpoints in clinical trials

3 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000470

A meta-analysis of the placebo rates of remission and response in clinical trials of active ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000470

Effects of the endpoint adjudication process on the results of a randomised controlled trial: the ADVANCE trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000470

Outcome measurement in clinical trials for Ulcerative Colitis: towards standardisation

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000470

Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000470

Reliability and initial validation of the ulcerative colitis endoscopic index of severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000470

Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000470

Review article: defining remission in ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000470

Vedolizumab as induction and maintenance therapy for ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000470

Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000470

Estimating sample sizes for binary, ordered categorical, and continuous outcomes in two group comparisons

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000470

Voting for image scoring and assessment (VISA)--theory and application of a 2 + 1 reader algorithm to improve accuracy of imaging endpoints in clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000470

Central endoscopy reads in inflammatory bowel disease clinical trials: The role of the imaging core lab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000470

Lessons learned from independent central review

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000470

Converging goals of treatment of inflammatory bowel disease from clinical trials and practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000470

Design and methodological considerations in the National Cooperative Gallstone Study: A multicenter clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000470

10.1097/MIB.0000000000000470

21 January 2018

Identifiers

DOI

1 reference

3 September 2017

1 reference